Sentiment: Strong Buy
ADMD has taken a big step forward. For those who had the patience to hold I think a nice run is coming soon.
And - There's the news! FDA testing and all looks on track! Here we go. Chew through some sellers and off to the races!
Sentiment: Strong Buy
KENNEWICK, Wash.--(BUSINESS WIRE)--Advanced Medical Isotope Corporation ("AMIC") (OTC: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today announced its progress in seeking FDA clearance for marketing of its lead product, the Y-90 RadioGel™ device.
CEO Jim Katzaroff and the lead scientific and medical advisory team from AMIC met at the FDA offices last week to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and AMIC team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States. AMIC intends to seek classification and clearance as a class II medical device through a de novo application.
In August, AMIC announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. AMIC is pleased to announce that IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing, commenced last Friday.
James C. Katzaroff, CEO of AMIC, stated: “We are pleased by the progress made thus far with both the FDA and our ongoing product development with IsoTherapeutics. After completing the first stage of product development with IsoTherapeutics ahead of schedule, we met with the FDA along with Dr. Darrell Fisher from our Medical Advisory Board, and we’re confident that we have clarity on the FDA expectations which are critical to generating a complete data package for our next FDA submission.”
The Y-90 RadioGel™ device is one of several Y-90 brachytherapy products in development by AMIC that may provide a safer, quicker and less expensive treatment to certain cancers, including tumors deemed inoperable. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. It is estimated that the U.S. market represents approximately half of the global market. AMIC believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers with its Y-90 product suite. A new study published in the British Journal of Cancer claims 1 in 2 men and women will be diagnosed with a cancer at some point in their lives. AMIC's mission employs in vivo delivery systems to aid medical practitioners and medical researchers in the treatment of diseases such as cancer, and the Y-90 brachytherapy products show excellent promise for this purpose.
If it was good news there would be buyer interest with strong volume and we would be most of the way to .0040, but we are not.
So here is the deal. The next time there is a PR try to refrain from calling it news until it is. In my opinion If it is not news then sell on it to the newbies.
Today they are now delayed in providing news, which it is not, it would be an update on the start of the RadioGel study by ISO. This update is already known to come as it is in the last PR about selecting ISO. That in my opinion is an update you could sell on because some would say it is news and to buy on it.
News embedded in a PR on the start of the study, whenever that really happens, could be clarity on the cost and how it will be paid. Remember in my opinion Series A Preffered Convertible shares , or notes, are worthless today due to the fact there are no shares to cover them. They are "when issued" shares and could be quite dilutive to shareholders like my self today and into the future. Stock splits meen nothing but increasing the AS and issueing those shares to cover Preferred Series A can be quite dilutive if sold into the market in mass. Much like toxic debt holders did to us in 2014. Check the chart and the SEC filings increasing authorized share count last year and before.
Always interesting to watch. Maybe I/we will get rich with AMIC some day. Hoping so!
Good volume and interest level is clearly still in ADMD. Ready for catalyst and lift off. Lot's of things going on that should be ready soon (very soon) for PR. GLTA $ADMD
Sentiment: Strong Buy
I would of thought that by now Stupid would have made a big enough fool out of himself but I guess thats why he's called Stupid.
fancy accounting? its accounting......they issued debt, then the debt holders eliminated toxic debt for preferred stock.......toxic debt would equal 10x the amount of preferred stock issued if they let it go toxic again....accounting tricks? you're clueless
In fact very little has changed. It is a change of "the wrapper". No debt has disappeared or been paid back. There is no money to do so. It is fancy accounting. If it was good news, and debt was retired, then it may actually show up in the share price. The share price tells ALL, even in micro-cap land. This in fact was not even news, they had already announced some time ago that " this" was going to happen but we did not know until the Series A Preferred Convertible was created.
It is for this reason I keep saying, be careful as "it" may not be news at all. When you realize that you sell your shares to the newbies who buy first and ask questions later. Hopefully you are selling for a profit too. Look at the last couple "news" events. Quick up and then back down and newbie loses money. Check that long term chart, what direction has it been going? The trend is your friend on this one if you are trading and can figure it out.
That is the problem, only a couple folks on this message board even read the all important financial jargon, much less understand it. In my opinion no not good, but it has more to do with just this financial jargon. I just post it because it does seem like many do not actually read it. It is from the most recent SEC Form 8k. There has been a lot of "big things" filed with the SEC lately from AMIC (ADMD). Some think it is great but you have to take "it" with the whole, not just as a piece.
Insiders, at least for now, have effectively separated themselves from the shareholders of 2 billion shares of ADMD. They no longer hold hardly any of the kind of stock you and I have. They used to really be one of us....no more the case. They have reduced their risk substantially if the company does not work out IMO.
Also, not boilerplate. Specific terms to preferred (other posts) and splits. I can tell by posts that SEC filings are not read here by posters. R/S is 95% not a positive for common share holders. A CTIC has done them and the only beneficiaries have been insiders and tutes. No different here. I think most shareholders in AMIC do not have limitless capital to keep buying stock into dilution and that is exactly what happens after R/S increas A/S, issue A/S to converted Preferred and sell those shares into market. There you go, a one year plan for what will happen with, guess what, 95% certainty. It is never good to own a company issueing any sort of financing device that is based in issueing something covered by shares that do not exist. Often times these shenanigans of over issuance are found out to late in an SEC filing. In this case they have enough integrity to tell you that they are doing it.
What is even funnier is they come right out at last and tell us we do not even get to vote. They have no interest in even seeing how many disapprove. No matter what Jim K says on an interview last spring/summer it is no longer valid. They have told us that 2 billion shares of common held today does not matter so to hell with the vote.
First time I have seen that before and I would like to think I have seen a lot in my life for stocks trading from $.0001 to $500 a share.
Onward and upward. If volumes, interest, does not improve these shares are not going to appreciate and the only thing getting sold will be preferred to insiders. Watch out for news that is not really news. You have posted three times. Does not represent your time following the stock but if it does correlate then you better study like heck. At one point early last summer I had a very significant investment into this stock. I am out for all sakes and purposes now. I wouldn't have taken all that profit without a gut feeling. Just a gut feeling is all. Been following since '08 or so.
Ube go back further, CEO interviews and such. You would have to understand the stock and company, previous statements, actions and cultures. Understand two failed submittal for FDA approval and then final actions of creating preferred. You would have to understand the financings previous, have listened to the conference calls. All I can say is the "texture" has changed. Not sure how to describe it. Recent actions though continue to add up to a far more aggressive posture by the company that is not common investor friendly in any way. I have posted enough here for a long to get it and that is really all that matters. Many of us have substantially exited our positions I believe some with good gains many others with losses.
Company has an extremely long way to a conclusion now to required testings, then submittal and after that who knows. AMIC will probably be alive for some time to come. Advancing the company though with a Preferred that is not covered by common is no way to raise capital. You do kind of need capital to advance studies that can generate positive news, and you need results to get the share price to rise. Maybe you will see what I meen at some point.